



Johann de Bono

Contact

Johann de Bono

Publications (11)

Vogl U, Mottet N, Padhani A, Roach M, Rubin M, Sartor O, Small E, Smith M, Soule H, Sydes M, Tombal B, Omlin A, Gillessen S, James N, Halabi S, Beer T, Davis I, Shore N, Sweeney C, Ost P, Attard G, Bossi A, de Bono J, Drake C, Efstathiou E, Fanti S, Fizazi K, APCCC 2019 expert panel. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. *Eur J Cancer* 2021; 160:24-60.

Omlin A, Ryan C, Rubin M, Roach M, Reiter R, Pritchard C, Poon D, Parker C, Padhani A, O'Sullivan J, Ost P, Oh W, Murthy V, Murphy D, Mrabti H, Mottet N, Morris M, Saad F, Sade J, Zapatero A, van Oort I, Türkeri L, Tombal B, Taplin M, Sydes M, Sweeney C, Suzuki H, Steuber T, Sternberg C, Soule H, Smith M, Small E, Shore N, Scher H, Sartor O, Morgans A, Millman R, Evans C, Efstathiou E, Eeles R, Duran I, Drake C, de Bono J, Davis I, Clarke N, Chi K, Bristow R, Briganti A, Bossi A, Bjartell A, Beltran H, Beer T, Attard G, Fanti S, Feng F, Maluf F, Logothetis C, Leibowitz R, Khauli R, Kantoff P, Kanesvaran R, James N, Hussain M, Hofman M, Higano C, Heinrich D, Heidenreich A, Halabi S, Gleave M, Frydenberg M, Fizazi K, Gillessen S. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *Eur Urol* 2020; 77:508-547.

Pérez-López R, de Bono J, Morris M, Omlin A, Vargas H, Fanti S, Oyen W, Padhani A, Tunariu N, Koh D. Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. *Radiology* 2019; 292:273-286.

Fanti S, Montironi R, Ost P, O'Sullivan J, Padhani A, Schalken J, Scher H, Tombal B, van Moorselaar R, Van Poppel H, Vargas H, Walz J, Weber W, Wester H, Lecouvet F, Hicks R, Herrmann K, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, de Bono J, Fizazi K, Gillessen Sommer S, Gledhill S, Haberkorn U, Oyen W. Consensus on molecular imaging and theranostics in prostate cancer. *Lancet Oncol* 2018; 19:e696-e708.

Omlin A, Ryan C, Rubin M, Roach M, Pritchard C, Parker C, Padhani A, Ost P, Oh W, Murthy V, Mottet N, Morris M, Morgans A, Maluf F, Saad F, Sartor O, Wiegel T, Valdagni R, Tombal B, Tannock I, Sydes M, Sweeney C, Suzuki H, Sternberg C, Soule H, Smith M, Shore N, Sella A, Scher H, Logothetis C, Kramer G, Khauli R, Dos Reis R, de Bono J, Davis I, Daugaard G, Clarke N, Chung B, Castellano D, Carver B, Bristow R, Bossi A, Beltran H, Beer T, Attard G, Drake C, Eeles R, Kellokumpu-Lehtinen P, Kantoff P, James N, Higano C, Heidenreich A, Halabi S, Gleave M, Frydenberg M, Fizazi K, Feng F, Fanti S, Evans C, Efstathiou E, Gillessen Sommer S. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *Eur Urol* 2017

Lorente D, Hall E, IJzerman M, Terstappen L, Payne H, Mateo J, Perez R, Tunariu N, Bianchini D, Porta N, Kolinsky M, Rescigno P, Miranda M, Gilman A, Omlin A, Pezaro C, Mehra N, Ravi P, de Bono J. Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. *Eur Urol Focus* 2016; 4:235-244.

Lorente D, Crespo M, Flohr P, Mateo J, Altavilla A, Ferraldeschi R, Bianchini D, Attard G, Tunariu N, Miranda S, Riisnaes R, Omlin A, Zafeiriou Z, Nava-Rodrigues D, Pérez-López R, Pezaro C, Mehra N, Sheridan E, Figueiredo I, de Bono J. Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. *Clin Genitourin Cancer* 2016; 14:485-493.

Ferraldeschi R, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, Altavilla A, Mateo J, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, de Bono J. PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. *Eur Urol* 2014

Mukherji D, Omlin A, Pezaro C, Shamseddine A, de Bono J. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. *Cancer Metastasis Rev* 2014; 33:555-66.

Pezaro C, Omlin A, Lorente D, de Bono J. Management of patients with castration-resistant disease. Hematol Oncol Clin North Am 2013; 27:1243-60, ix.

Omlin A, Attard G, Parker C, Thompson E, Maier G, Ferraldeschi R, Olmos D, Bianchini D, Sandhu S, Mulick Cassidy A, Mukherji D, Pezaro C, de Bono J. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 2013; 64:300-6.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch